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Purpose/Objective: The assessment of the procedure safety in 
Intraoperative Radiotherapy (IORT) with mobile machines analyzes the 
risk of using the dedicated equipments and the misunderstandings in 
work flows. This procedures optimization should led to a prospective 
analysis and errors management that helps to identify potential 
failure modes and severity of the clinical consequences on patients. 
Aim of this experience is to review the Intraoperative Radiation 
Therapy process with the mobile linear accelerator Novac7, applying 
the Failure Mode and Effects Analysis (FMEA) to improve patients 
safety.  
Materials and Methods: The FMEA analysis provides a systematic 
method for finding vulnerabilities in a process before they result in an 
error. Three steps were identified: 1) process study with involved 
phases and activities; 2) hazard analysis with identification of possible 
failure modes and their effects, calculating for each failure mode the 
risk probability number(RPN) by the product of three scores (severity, 
frequency and detectability of that failure, each on a scale of 1 to 
10); 3) planning additional safety measures scored for effectiveness (1 
to 10) and feasibility (1 to 10). The RPN scores can span a range of 1 
to 1000; decisions are made based on the RPN values. The RPN value 
less than 125 was considered of little concern of risk. 
Results: The FMEA analysis was tested on breast cancer patients 
treated with IORT in our centre from 2005 on. The procedure was 
examined in a multidisciplinary view. With regard to a medical 
perspective the main reported clinical risks were in patient’s 
identification, indication to treat and timing with other therapies. In 
our experience the use of standardized protocols and a good informed 
consent modality, shared between surgeon and radiotherapist, was 
able to reduce the risk and was a simple way to implement the 
results. The dose prescription, consisting of the volume to be treated, 
the used technique, the dose, energy and organs at risk (OAR) 
identification were checked with a written list and a double control, 
shared between physicist and radiotherapist, was performed. 
Technically each point of IORT was described and a report of the 
procedure was always inserted in the medical chart and into the 
software dedicated to Radiotherapy Department. Physical critical 
failure modes were identified as incorrect data entry at treatment 
console and underestimation of CTV extension, resulting in wrong dose 
distribution and CTV under-dosage. Several safety solutions were 
proposed, including in vivo dosimetry. 
Conclusions: FMEA is a widely-used tool for improving safety and can 
be easily adapted for IORT optimization. New risk management 
strategies can provide highly qualified procedures for avoiding the 
increase in acute and late toxicity and in the reduction of tumor 
control. The impact of this tool is under study.  
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Purpose/Objective: There is no consensus on boost target volume 
delineation in conserved breast in locally advanced breast cancer 
(LABC) after neoadjuvant chemotherapy (NACT). Inclusion of 
prechemotherapy target volume has the disadvantage of large 
volumes which will have a detrimental effect on cosmesis. Inclusion of 
postchemotherapy target volume has the advantage of smaller target 
volume but there could be a higher risk of recurrence.We therefore 
did a retrospective analysis of LABC patients who underwent breast 
conservation (BCS) after NACT to assess whether post NACT target 
volumes are adequate for achieving local control. 
Materials and Methods: Patients of LABC who underwent BCS and 
radiotherapy after NACT, registered between 2007-2011 were the 
subject of our analysis. After BCS,patients received whole breast and 
supraclavicular radiotherapy (50Gy/25 fractions/5wk or 42.4Gy/16# / 
3 wk) which was followed by boost (10-16Gy/5-8#/1-1.5wk). After 
evaluating patterns of recurrence in these patients, the information 
on lumpectomy specimen size, method of estimating tumour boost 
field size (whether based on visible scar, tumour cavity on CT scan, 
prechemotherapy tumour size or postchemotherapy tumour size) was 
sought to gain an insight on whether these had an impact on the local 
recurrence. 
Results: 43 patients were the subject of this analysis. The median age 
was 47 years,42% were premenopausal and 58% were postmenopausal. 
Histopathological subtypes were luminal A (23%), luminal B (23%), Her- 
2 type(14%) and basal type (40%). (47.7%)patients had stage II 
disease,12 (27.2%) had III A and 10 (22.7%) had IIIB disease at 
presentation. After NACT 33.3% patients acheived CR (complete 
response), 54.8% PR (partial response) and 11.8% had SD (stable 
disease). The surgical margins around tumour in lumpectomy 
specimens were based on pre-chemotherapy tumour size in all 
patients. Radiotherapy planning scan revealed tumour cavity in 33 
patients and clips in 19 patients. Boost target delineation was based 
on visible scar: 4 patients ( 9.7%), tumour cavity: 5 patients (12.1%), 
prechemotherapy target volume : 5 patients (12.1%) and post 
chemotherapy target volume:27 patients (65%). 2 patients did not 
receive a boost. At a median followup of 27.2 months (4-71 
months),no patient had ipsilateral breast tumour recurrence (IBTR), 
one patient had ipsilateral axillary node recurrence and four patients 
had distant metastases. 
Conclusions: Postchemotherapy target volume seems to be safe as 
boost volume delineation for radiotherapy in patients with LABC who 
undergo BCS after NACT. 
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Purpose/Objective: To assess the comparative effectiveness of 
traditional (normal-dose) and reductional (low-dose) variants of 
postmastectomy chest-wall irradiation with the criteria of local 
control, overall and relapse-free survival rates, frequency of 
postradiation cardiac complications. 
Materials and Methods: Two groups of patients with breast cancer IIB 
– IIIB stages were studied: the 1st group – variant of normal-dose (50 
Gy to chest wall in 25fractions) radiation therapy with/without 
chemotherapy (129 patients), the 2nd group – variant of low-dose (40 
Gy to chest wall in 20 fractions) radiation therapy with/without 
chemotherapy (82 patients). In all cases radiation therapy followed 
Madden mastectomy. Dose to regional areas (46-50 Gy according to 
the number of metastatic lymphatic nodes) as well as neoadjuvant 
and adjuvant chemotherapy regimes was similar in both groups. The 
median follow-up was 111 and 95 months for the 1st and 2nd group 
respectively. 
Results: Frequency of 5-year actuarial local-regional progression in 
case of normal-dose and low-dose variants was estimated as 6,2±2,1% 
and 3,7±2,1% respectively (p=0,4). Metastases developed in 34,6±4,2% 
and 19,5±4,4% of patients in the 1st and 2nd group (p<0,05). 5-year 
relapse-free survival was53,5±5,4% and 71,5.±6,4% and overall survival 
- 65,3±5,6% and 72,2±6,3% for the 1 and 2 group respectively (?=0,08). 
Late failure in ECG in patients with left-side chest-wall irradiation 
were detected in 55±11,1% in the low-dose group comparing to 
75±9,7% in the normal-dose group (?<0,05). 
Conclusions: There are no statistically significant differences in local 
control, overall and relapse-free survival rates of traditional normal-
dose and low-dose variants of postmastectomy chest-wall irradiation. 
This method of dose-reduced postmastectomy chest-wall irradiation in 
compliance with modern systemic treatment allows to decline risk of 
cardiotoxicity with the maintenance of the treatment effectiveness 
achieved by using traditional method. 
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Purpose/Objective: The aim of our report – to compare the results of 
different regimes of whole-breast irradiation (accelerated 
hypofractionated, dynamic hypofractionated and, standard radiation 
treatment) following breast-conserving surgery for breast cancer I-IIA 
stages. 
Materials and Methods: From 2000 till 2005 yy 333 patients aged R54 
years received whole-breast irradiation following breast-conserving 
surgery (lumpectomy + axillary and internal lymphatic dissection). The 
most commonly seen invasive ductal carcinoma (55%), the rare - 
Invasive lobular carcinoma (27%), Invasive ductal cancer with 
extensive in situ component (3%) and special forms (15%). Metastasis 
in ipsilateral axillary lymph nodes fixed in 17,4% cases. All patients 
received whole-breast irradiation with different regimens RT: 1 group 
- accelerated hypofractionated (3Gy per fraction over 2,5 weeks, total 
dose of 39Gy, N=112), 2 group – dynamic hypofractionated (5Gy per 
fraction - 2, then 2,5 per fraction - 15, over 3,5 weeks, total dose of 
47,5Gy, N=130) and 3 group - standard radiation treatment (2 Gy per 
fraction over 5 weeks, total dose of 45–50 Gy, N=91). We used three-
dimensional CT-based treatment planning, two traditional tangent 
radiotherapy fields 6-18 MV, changing the gantry angle, collimator 
angle, blocks to result in coverage of the breast while excluding the 
heart from the treatment fields and minimized dose to the lung. Local 
relapse: 0% (1 group), 0,9% (2 and 3 groups) at 5 years. Five-year 
S402  2nd ESTRO Forum 2013 
overall survival: 99,1% (1 group) vs. 97,7% (2 group) and 97,8% (3 
group), (p< 0.216). Five-year event free survival: 98,0% (1 group) vs. 
92,2% (2 group)and 94,5% (3 group), (p < 0.0345). Only 8% of the 
patients of the 1 group developed grade 2 erythema , 17,7% of the 
patients of the 2 group (p=0.043) and 14,3% of the patients of the 3 
group (p<0,048). Side effects after 5 years: 35,7% (1 group) vs. 53,8% 
(2 group) and 42,8% (3 group), (p < 0.05). Excellent and good cosmetic 
results after 5 years: 79,4% (1 group) vs. 65,4% (2 group) and 73,6% (3 
group), (p < 0.049). 
Results: No difference in distant metastasis and overall survival 
between different regimes of RT. 
Conclusions: Accelerated hypofractionated RT (3 Gy per fraction over 
2,5 weeks, total dose of 39Gy) decrease in local relapse, acute 
toxicity and adverse effects, increase five-year event free survival and 
cosmetic results after accelerated hypofractionated vs. dynamic 
hypofractionated and standard radiation treatment.  
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Purpose/Objective: Whole breast irradiation(WBI) (50 Gy in 25 daily 
fractions of 2 Gy over 5 weeks ± boost of 10 Gy to the tumor bed) is 
the standard treatment after breast-conserving surgery (BCS) for early 
breast cancer (EBC). Recent randomized trials have confirmed that 
hypofractionated whole breast irradiation (WB-HyRT) is an effective 
alternative to conventional WBI for its equivalence in terms of local 
tumorcontrol, patients survival and late post-radiation effects. The 
aim of our experience was to evaluate feasibility, compliance and 
acute and early late toxicity of WB-HyRT. 
Materials and Methods: From February 2011 to November 2012, 41 
patients with EBC (pT1-2, pN0-1, pM0), who underwent BCS and 
sentinel nodal examination with or without axillary dissection, were 
treated with adjuvant WB-HyRT using 3D conformal radiotherapy. The 
median age was 73 years (range 60-84). The whole breast was treated 
with two opposed tangential fields, for a total dose of 42.56 Gy in 16 
daily fractions (2.66 Gy/f), with Linac 6 MV. Five patients received 
chemotherapy antracicline and taxan based, before RT. 36 patients 
received adjuvant hormonal therapy (FATA protocol), because the five 
remaining cases had hormone receptors negative. Toxicity was 
evaluated according to RTOG/EORTC toxicity criteria. The acute 
toxicity (within 6 months after the end of RT) was evaluate during RT 
course with weekly clinical examination, and early late toxicity wase 
stimated during standard follow-up.  
Results: the mean follow-up was 9 months (1-21 range). All patients 
completed radiotherapy without break for toxicity end with a good 
compliance to the treatment. All patients were evaluated for acute 
toxicity and 21 for early late toxicity. Acute skin toxicity was G3 in 1 
patient (2,4%), G2 in 6 pts (14,6%), G1 in 26 pts (63,4%) and G0 in 8 
pts (19,5%). Acute hematological toxicity was G3 in 2 pts (5%), G1 in 3 
pts (7,3%), G0 in 36 pts (87,7%) and none G2. None patients suffered 
from cardiac or pulmonary or other acute toxicity. Early late skin 
toxicity observed was G1 in 5 pts (23,8%) and G0 in16 pts (76,2%). 
Only one (4,2%) patient had G1 early late hematological toxicity. No 
other early late toxicity were register. 
Conclusions: Our results showed that WB-HyRT is feasible and well 
tolerated, with few acute and early late toxicity and good compliance 
to the treatment. In older women with EBC the hypofractionated 
schedule represent a biologically acceptable alternative to the 
traditional 6 weeks regime. Also the reduction of the overall 
treatment time leads advantages in economic saving terms and can 
have a benefit in LINAC waiting list too. 
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Purpose/Objective: Whilst 3dCRT is widely used for the adjuvant 
treatment of breast cancers, the use of ARC therapy using Helical 
Tomotherapy(HT) is gaining momentum in specific centres. 
Materials and Methods: Two Radiotherapy(RT) plans (HT and 3DCRT) 
for ten adjuvant chest wall and breast including supraclavicular fossa 
(SCF) treatment were compared. Dose to target volumes (TV) 
including SCF (2 with gross nodes requiring boost), internal mammary 
chain(IMC, 3 patients), lung,heart, brachial plexus were compared. 
Homogeneity index (HI) and conformityindex (CI) was calculated for 
TV coverage. A hypofractionated 40Gy in 15fraction schedule was 
prescribed to the PTV.  
Results: TV coverage both for chest wall and whole breast(n=2) was 
better with HT; median dose (±SD) of 41.58Gy (±1.92) for HT and 
38.97(±3.41)using 3DCRT; p=0.01. SCF median dose 41.62Gy (±2.85) 
vs. 31.86Gy (±12.34)respectively (p-0.04) was better with HT whilst 
IMC coverage too was betterwith HT. HI and CI were both better with 
HT than 3dCRT. Brachial plexus received higher maximum 
(41.31Gy/33.99Gy) and median dose (17.34Gy/4.96Gy) with HT. The 
mean dose to the heart was higher with HT than 3DCRT; 5.65Gy versus 
0.79Gy for right sided tumours(n=4) and 9.69Gy vs.1.69Gy for left 
sided tumours(n=6) without IMC coverage(n=3) and 11.56 Gy vs.2.34 
Gy for left sided tumours with IMC coverage(3DCRT plans generated 
without IMC coverage). For left sided tumours with IMC irradiation, 
the V15Gy and V20Gy(mean±SD) of the heart was significantly higher 
with HT (24.55±12.18% vs.4.35±1.95% and 15.83±9.51 vs.3.96±1.78%) 
respectively..Those without IMC coverage,the mean V15Gy and V20 Gy 
of heart was 21.62% vs.5.38% and 10.42% vs.4.82% respectively. 
Contralateral mean lung dose was also higher with HT (3.38Gy 
vs.0.22Gy).Mean V5Gy and V15Gy of contralateral lung was 19.17% 
vs.0% and 1.3% vs. 0% respectively in HT versus 3dCRT. The opposite 
breast too received a higher mean dose with HT than 3DCRT (7.02Gy 
vs. 0.26Gy) 
Conclusions: HT provided a better target volume coverage including 
coverage of IMC and SCF and Breast/Chest wall without the use of 
field junctions. The better CI with HT was achieved at the expense of 
higher mean dose to the OARs like heart, contralateral lung, opposite 
breast and brachial plexus. Dosimetric data suggests little evidence 
for the routine use of HT in adjuvant breast radiotherapy but it could 
be considered in selected complex volumes including when treating 
the IMC, SCF and boosting gross residual disease post chemotherapy. 
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Purpose/Objective: Localization of the tumor bed of breast cancer is 
crucial for accurate planning of boost irradiation. Lumpectomy cavity 
and surgical clips provide localizing information about tumor bed. 
However, defining the tumor bed is often difficult because of 
presence of unclear lumpectomy cavity and lack of certain 
information such as absence of surgical clips. In the present study, we 
evaluated the role of diagnostic PET-CT in localization of the tumor 
bed using deformable image registration (DIR). 
Materials and Methods: We selected twenty-five patients who had a 
preoperative PET-CT performed and underwent breast-conserving 
surgery with surgical clips in tumor bed. In every individual patient, 
two target volumes were separately delineated on planning CT; 1) 
planning target volume based on surgical clips with a margin of 1 cm 
(PTVclip) and 2) gross tumor volume based on 90% of maximum SUV on 
PET-CT registered by DIR (GTVPET). The percent of GTVPET in PTVclip 
(Vin) was calculated and distance between center points of two 
volumes (Dcenter) was also measured. 
Results: Mean Dcenter between two volumes was 1.4 cm (range, 0.33 – 
2.53). Mean Vin was 94.8% (range, 60.9-100) and 100% in 18 out of 25 
patients. When compared to the center of PTVclip, the center of GTVPET 
tended to be located posteriorly (mean 0.3 cm, standard deviation 
0.6), laterally (mean 0.3cm, standard deviation 0.8) and inferiorly 
(mean 0.4 cm, standard deviation 0.9). 
Conclusions: DIR of diagnostic PET-CT can be a considerable 
reference for the localization of tumor bed on planning CT for breast 
cancer radiotherapy. 
 
 ELECTRONIC POSTER: CLINICAL TRACK: GASTRO-
INTESTINAL TUMOURS (UPPER AND LOWER GI)  
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